Dizal Scores First JAK1 Approval For Advanced PTCL

China Nod

 
• By Dexter Jie Yan

China's Dizal has won the first approval worldwide, in its home market, for a JAK1 inhibitor in relapsed/refractory peripheral T-cell lymphoma (PTCL), based on a pivotal Phase II trial. The biotech is also planning a Phase III study with the molecule for second-line PTCL.

first line treatment
Dizal's golidocitinib becomes world’s first approved JAK1 inhibitor for second-line PTCL • Source: Shutterstock

More from China

More from Focus On Asia